Xiaohong Du

Dr. Xiaohong Du


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2020 in Inflammation
Verified
Journal Article
Closed access
PDF file
LCLeifeng Chen
Leifeng Chen
QLQiang Lu
Qiang Lu
FDFumou Deng
Fumou Deng
SPShengliang Peng
Shengliang Peng
JYJiajia Yuan
Jiajia Yuan
XDXiaohong Du
Xiaohong Du

16 February 2015 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
XDXiaohong Du
Xiaohong Du
RXRenjie Xiao
Renjie Xiao
FXFan Xiao
Fan Xiao
YCYong Chen
Yong Chen
FHFuzhou Hua
Fuzhou Hua
GXGuohai Xu
Guohai Xu

1 January 2024 in American Journal of Cancer Research
Verified
Journal Article
Closed access
ZLZhiqiang Liu
Zhiqiang Liu
LLLiang Li
Liang Li
LLLei Liu
Lei Liu
ZZZhengming Zhu
Zhengming Zhu
YYYi Yu
Yi Yu
XDXiaohong Du
Xiaohong Du
Pyruvate Dehydrogenase Kinase 3 (PDK3) has emerged as a significant player in various cancer types, yet its specific impact on cancers including colon cancer remains ambiguous. Through pan-cancer analysis using TCGA data, we found that the expression of PDK3 and the composition of the immune microenvironment for different tumors were highly heterogeneous across tumors. PDK3 is highly expressed in colorectal cancer and may promote tumor proliferation by activating PI3K-AKT signaling. In addition, we found that PDK3 was able to inhibit tumor antigen presentation signals to suppress immune killing. High PDK3 expression predicts less CD8+ T cell infiltration and effector function. Moreover, inhibition of PDK3 expression bolstered CD8+ T cell-mediated cytotoxicity CD8+ T cell infiltration and activation in vivo. Notably, PDK3 was found to facilitate STAT1 activation and elevate programmed death-ligand 1 (PD-L1) expression in colon cancer cells. Importantly, PDK3 inhibition combination with PD-1 blockade significantly activates the infiltrated CD8+ T cells to suppress tumor growth and improves the survival benefit in several murine tumor models. In summary, these findings underscore PDK3’s role in fueling colon cancer growth by orchestrating PI3K-AKT signaling and PD-L1 expression and dampening CD8+ T cell function.